Mentors provide a space where anything can be discussed


Our Board Mentor, Mark Silver, talks to us about how mentors provide a space where anything can be discussed. Mark has a wealth of Board experience as a Chair, CEO and CFO in competitive markets with both PE-backed and listed companies. Now in his portfolio career, Mark is Chair of Cordic Ltd, a leading fleet management SaaS provider to UK taxi, private-hire and courier service sectors, owned by Oakfield Capital Partners, and was recently appointed Chair of Horizon Care and Education Group, a leading national provider of childcare, education and leaving care services, backed by Graphite Capital. 

Share this with your Community



Contributor
Mark Silver
Board Mentor
Criticaleye


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

BLOG | The CEO-CFO Partnership: Driving Strategic Alignment

The relationship between the CEO and CFO has never been more important.  In a business environment defined by economic uncertainty, AI-driven transformation and heightened stakeholder expe...


Click here to download this insight

Building an AI-Ready Workforce

AI is reshaping ways of working faster than most organisations can adapt, putting talent strategy at the top of the Board agenda. Criticaleye's Anna Mitchell asks Board Leaders and CPOs with hands-on experience o...


Click here to download this insight

Driving the Next Phase of Growth at RAC

In this interview with Criticaleye Senior Editor Jacob Ambrose Willson, RAC’s CFO, Jo Baker, talks through how she has helped to steer the business through a significant transformation during the last several year...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 193




AlixPartners Stream LACE Partners London Stock Exchange Group Southern Water NATS Drax Group plc Rolls-Royce Legal & General Global Payments NatWest Group Mayborn Group British Land Hitachi Solutions E.ON UK Lightsource bp GlaxoSmithKline plc